---
title: "Why Is VivoSim Labs Stock Falling Thursday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292931999.md"
description: "VivoSim Labs (NASDAQ: VIVS) stock plummeted over 26% following the announcement of a $4 million private placement priced at $0.85 per share. The offering involves selling 4.71 million shares and warrants, raising concerns about shareholder dilution. Proceeds will support working capital and general corporate purposes."
datetime: "2026-07-16T16:24:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292931999.md)
  - [en](https://longbridge.com/en/news/292931999.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292931999.md)
---

# Why Is VivoSim Labs Stock Falling Thursday?

**VivoSim Labs Inc.** (NASDAQ:VIVS) stock fell more than 26% on Thursday after the biotechnology company announced a private placement priced at 85 cents per share, raising investor concerns about potential shareholder dilution.

## Private Placement Sparks Dilution Concerns

VivoSim Labs entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 4.71 million shares (or equivalent securities) and accompanying warrants at a combined effective price of $0.85 per share.

The company raised approximately $4.0 million in gross proceeds before fees and expenses.

The warrants, exercisable at $0.85 per share upon shareholder approval, will remain valid for five years.

The company also plans to amend certain May 2024 warrants covering 520,833 shares by lowering the exercise price from $9.60 to $0.85 per share, subject to shareholder approval, while extending their term to five years from the approval date.

The offering is expected to close around July 17, 2026, with proceeds earmarked for working capital and general corporate purposes.

**Read Also: Vivosim Discloses Eli Lilly Milestone Payment & Outlook**

## What VivoSim Labs (VIVS) Does

VivoSim Labs, formerly Organovo Holdings, is a biotechnology company focused on developing FXR314 for inflammatory bowel disease (IBD), including ulcerative colitis (UC).

The company utilizes three-dimensional (3D) human tissues to provide insights into liver and intestinal toxicology, which is increasingly relevant as regulatory bodies move towards refining animal testing requirements.

The recent announcement of a private placement is significant as it reflects the company’s need for capital to support its ongoing research and development efforts.

As VivoSim continues to position itself within the evolving biotech landscape, its ability to secure funding while managing investor sentiment will be crucial for its future growth.

## VivoSim Labs Stock Price Action

**VIVS Price Action:** VivoSim Labs shares were down 26.52% at $0.62 at the time of publication on Thursday, according to Benzinga Pro data.

_Photo via Shutterstock_

### Related Stocks

- [VIVS.US](https://longbridge.com/en/quote/VIVS.US.md)
- [ONVO.US](https://longbridge.com/en/quote/ONVO.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [VivoSim Labs issues 9,896,718 shares on warrant exercises](https://longbridge.com/en/news/295105778.md)
- [VivoSim Labs announces annual shareholder meeting](https://longbridge.com/en/news/295411044.md)
- [BIO-key enters deal for investor to exercise warrants at USD 4.06 per share, raising USD 2.5 million](https://longbridge.com/en/news/295537205.md)
- [Replimune amends filing to correct pre-funded warrant beneficial ownership limits](https://longbridge.com/en/news/295516949.md)
- [Aim Immunotech’s Aggressive Equity Issuance Raises $10.4M but Poses Major Dilution Risk for Shareholders](https://longbridge.com/en/news/295371378.md)